Nektr Technologies
Nektr – Developed By Nature, Refined By Science.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
€1.0m | Seed | ||
| Total Funding | 000k | ||
Related Content
Nektr Technologies, founded in 2017 by medtech entrepreneur Frank Boyle, operated from Sligo, Ireland, with a focus on biotechnology. Boyle, who previously founded and successfully sold ProTek Medical to Koch Industries in 2016, brought his experience to this new venture.
The company's core business revolved around the development of a synthetic compound known as A3IS. This compound was engineered to possess anti-bacterial, anti-fungal, and anti-viral properties, positioning it as a potential solution to challenges in both human and animal health. Nektr Technologies aimed to address the global issue of antibiotic resistance by developing treatments for multi-drug resistant pathogens. The primary applications for A3IS included treatments for onychomycosis (a fungal nail infection), dermatological conditions, nasal decontamination, and coatings for medical devices. The company's business model appeared to be centered on the research, development, and subsequent commercialization of this proprietary technology.
A significant milestone for Nektr Technologies was securing €1 million in funding in May 2021. This investment round was notably supported by the Western Development Commission, which provided half of the capital, alongside other investors including Enterprise Ireland. The funds were intended to advance the clinical trials of A3IS and explore its broader commercial applications. At the time, the company was reportedly in the final stages of a Phase 3 clinical trial for the efficacy of A3IS in treating onychomychosis.
Despite its promising start and the backing of notable investors, reports from late 2023 and company information databases indicate that Nektr Technologies Limited has entered liquidation. A meeting of creditors was reported to have taken place in December 2023, and the company is also described as "deadpooled".
Keywords: Nektr Technologies, Frank Boyle, A3IS, antimicrobial compound, antifungal, antiviral, biotechnology, Sligo, ProTek Medical, Western Development Commission, Enterprise Ireland, onychomycosis treatment, medical device coatings, antibiotic resistance, liquidation, deadpooled, pharmaceutical preparations, human health, animal health, synthetic compound